Hold TMO with structural thesis intact but refined tactical discipline: add trigger requires two consecutive closes above $605 with RSI >65 and MACD positive, tactical trim trigger at $570 with RSI <50 and MACD deteriorating, hard stop at $533.
The HOLD verdict reflects convergence on direction across all three analysts, with the structural thesis intact (golden cross completed, 200 SMA as multi-month floor, $6.24B TTM FCF, 70% recurring revenue, 0.85 defensive beta) but path forward requiring patience plus tight technical discipline. The aggressive analyst's central forecast error is treating the bull case as base case; the conservative analyst overreaches on downside scenario requiring simultaneous macro, technical, and fundamental breaks. The neutral analyst's synthesis is operationally correct: require stricter confirmation before adding, not a single close. Risk-reward framing of risking $533 (9% downside) to make $619-$643 (6-10% upside) overstates asymmetry by measuring to technical levels rather than fundamental value. The disciplined response is to hold existing position, monitor three-deterioration signal (if MACD histogram deepens below -1.5 with sustained price weakness, that confirms distribution and warrants tactical trimming into any relief rally), and require confirmation before adding. The hard invalidation at $533 close remains the cleanest thesis-breaker.
Thermo Fisher is a high-quality, defensive growth-and-value compounder at a fair price with a catalyst-rich 12-18 months ahead, with asymmetric risk/reward favoring longs at current levels.
| Indicator | Value | Signal |
|---|---|---|
| RSI | 60.92 | bullish |
| RSI Peak | 74.55 on Aug 11 | neutral |
| MACD Line | 18.34 | bullish |
| MACD Signal Line | 19.82 | bullish |
| MACD Histogram | -1.49 | bearish |
| ATR | $14.60 | neutral |
| ATR Peak | $18.19 on Jul 28 | neutral |
| VWMA | $583.00 | bullish |
| Volume (Aug 17) | 667,064 shares | neutral |
| 10 EMA | $587.88 | neutral |
| 50 SMA | $530.80 | bullish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close below $533 (200 SMA on volume)
Then: Reassess to Underweight
Q2 2026 was a game-changer with strongest organic growth in five quarters and accelerating fundamentals
↩ rebuts: “Bear case completely ignores the seismic shift in TMO's fundamentals; Q2 organic growth was accelerating, not decelerating”
· concedes: Rising leverage is real: net debt rose from $30.7B to $38.5B YoY, debt-to-equity at 0.81, interest expense doubled from $726M (2022) to $1.42B (2025); 18x forward P/E bear case implies $495 price — a meaningful decline is possible if Q3 is missed; Year of underperformance relative to market; MACD histogram did flip negative; Integration risk on the $8.9B acquisition is real near-term
TMO at $585 is a structurally exposed mega-cap with deteriorating momentum, an aggressive valuation requiring near-perfect execution across 8 stacked assumptions, a goodwill-loaded balance sheet representing 48% of assets with rising leverage, and macro headwinds from higher-for-longer rates that will compress multiples.
EV: -9% to -20% · concedes: The $1.1B microbiology divestiture is indeed a clean exit; India expansion is real, albeit slow-moving; FDA clearances are genuine product additions; Q2 2026 headline numbers do show growth
→ vs conservative: Forward P/E of 21x requiring 48% EPS growth is mathematically true but analytically lazy—the $27.51 estimate already bakes in an already-closed, already-funded, already-contributing $8.9B acquisition; the conservative is pricing in failure as the base case and calling it prudence
→ vs conservative: Organic growth disclosure gap does not support 'mostly M&A' conclusion—10.5% revenue growth against a tough comp, 14% operating income growth, and 40.7% gross margin holding cannot be explained by inorganic revenue; the bears are extrapolating from a disclosure gap to a fundamental gap, and Q2 numbers refuted that
→ vs neutral: Waiting for RSI above 60, positive MACD histogram, breakout above $605, and RSI re-acceleration creates four stacked waits—by the time all four resolve simultaneously, buyer is at $620s, not $580s; that's paying a 10-15% premium for the same risk-adjusted return
→ vs conservative: Name a specific risk not already priced into the $533 hard stop level on a company generating $6B FCF, 70% recurring revenue, with raised guidance, portfolio being optimized through divestitures, and beta below 1.0
| 200 SMA | $532.00 | bullish |
| Bollinger Middle Band | $576.10 | bullish |
| Bollinger Upper Band | $619.16 | bullish |
| Bollinger Lower Band | $533.04 | bullish |
| Golden Cross | Confirmed in late July; 50 SMA crossed above 200 SMA | bullish |
Support: 576.1 · 533.04 · 532 · 530.8 | Resistance: 587.88 · 605 · 619.16
TMO is in a cautiously bullish medium-term uptrend following a May-August rally from ~$437 to $605, with the 50/200 SMA golden cross confirming structural trend reversal. Near-term momentum is cooling: RSI declined from 74.55 overbought peak to 60.92, and MACD histogram turned negative (-1.49) for the first time since late May, signaling a pullback within the uptrend. Price sits between Bollinger middle ($576.10) and upper ($619.16) bands with ATR compressing to $14.60, suggesting consolidation rather than breakdown. Support zones at $576 (BB mid), $532 (50/200 SMA cluster), and $533 (BB lower/200 SMA) define risk levels; $605 is the immediate resistance. ATR-based trailing stop reference is $570.91. Final transaction proposal: HOLD.
Market Cap
$216.49 B
P/E (TTM)
31.50
Forward P/E
21.28
PEG Ratio
1.92
Price / Book
4.11
EPS (TTM)
$18.59
Forward EPS
$27.51
Dividend Yield
0.32%
Beta
0.85
52-Week High
$643.99
52-Week Low
$435.27
50-Day Moving Avg
$528.79
200-Day Moving Avg
$532.60
Revenue 2022
$44,915 M
Revenue 2023
$42,857 M
Revenue 2024
$42,879 M
Revenue 2025
$44,557 M
Diluted EPS 2022
$17.63
Diluted EPS 2023
$15.45
Diluted EPS 2024
$16.53
Diluted EPS 2025
$17.74
Net Income 2022
$6,950 M
Net Income 2023
$5,995 M
Net Income 2024
$6,335 M
Net Income 2025
$6,704 M
Gross Margin (TTM)
~41.0%
Operating Margin (TTM)
18.75%
Net Profit Margin
15.04%
EBITDA Margin
~25.3%
FCF Margin
~13.5%
ROE
13.52%
ROA
5.13%
Total Assets
$113,174 M
Goodwill
$54,832 M
Intangibles
$18,606 M
Total Debt
$42,549 M
Net Debt
$38,485 M
Debt/Equity
0.81
Current Ratio
1.55
Working Capital
$8,296 M
Tangible Book Value
-$20.8 B
OCF 2022
$9,154 M
OCF 2023
$8,406 M
OCF 2024
$8,667 M
OCF 2025
$7,818 M
FCF 2022
$6,911 M
FCF 2023
$6,927 M
FCF 2024
$7,267 M
FCF 2025
$6,293 M
Share Repurchases 2025
$3,000 M
Dividends 2025
$636 M
Business Acquisitions 2025
$4,037 M
Q1 2026 Business Purchase
$8.872 B
Q2 2026 Revenue
$11.994 B
Q2 2026 Net Income
$1.736 B
Q2 2026 Diluted EPS
$4.68
Interest Expense 2022
$726 M
Interest Expense 2025
$1.42 B
Strengths
Concerns
Thermo Fisher Scientific is a high-quality defensive healthcare compounder with mega-cap scale ($216.5B), strong profitability (41% gross margin, 15% net margin), and consistent FCF generation ($6.3B). The company is currently digesting a $8.9B acquisition from Q1 2026 while delivering reaccelerated organic growth (+10.5% revenue, +9.3% EPS in Q2 2026). The stock trades at a premium TTM P/E of 31.5x but a reasonable forward P/E of 21.3x, with the key risks being M&A integration execution, rising leverage (net debt +25% YoY to $38.5B), and $54.8B of goodwill representing 48% of assets. The Q3 2026 earnings print will be a critical catalyst for validating the aggressive EPS growth embedded in the current valuation.
Macro: Risk-off tone across U.S. equities with major indexes (S&P 500, Dow, Nasdaq) ending lower on the week, driven by rising long-term yields, oil price spike, and renewed geopolitical risk. The 30-year Treasury yield hit its highest level since 2007, amplifying equity de-rating pressure for long-duration growth names. Trump threats related to Oman and the expiration of the US-Iran ceasefire have pushed crude sharply higher, with Libya pipeline geopolitics flagged as a further supply-side wildcard. The Fed is expected to hold rates with an 85% implied probability of no cuts in 2026, while the U.S. recession probability remains low at 8%. Japan recession probability jumped to 60% (+31.5pp WoW), a regional but not direct U.S. risk. FRED macro data was unavailable and not fabricated per protocol.